Subject:
- Active Substance: Vandetanib
- Name: Caprelsa®
- Therapeutic area: Medullary thyroid cancer
- Pharmaceutical company: Sanofi Aventis Deutschland GmbH
Time table:
- Start: 01.10.2021
- Final decision by G-BA: 18.03.2022
Final decision:
- No additional benefit proved